Kala Pharmaceuticals, Inc. announced today that it is dedicated to finding and developing new treatments for eye diseases. Its commitment to this mission is reflected in its extensive product pipeline, which includes a range of therapies for various ocular conditions. One of Kala's most promising product candidates is KPI-012, currently in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. The company's other products include EYSUVIS, a short-term treatment for the signs and symptoms of dry eye disease, and INVELTYS, a topical steroid for pain and inflammation following ocular surgery. Kala has also expanded its reach into preclinical development, with KPI-014 for the treatment of rare inherited retinal diseases. This diverse product portfolio underscores the company's commitment to innovation and advancing the field of ophthalmology. Kala Pharmaceuticals, Inc. was established in 2009 and is headquartered in Watertown, Massachusetts. Formerly known as Hanes Newco, Inc., the company changed its name in December 2009 to reflect its emphasis on eye disease treatments. With a strong focus on research and development, Kala Pharmaceuticals aims to make a difference in people's lives by improving eye health.